NCT04706936招募中1 期
Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma
Second Affiliated Hospital, School of Medicine, Zhejiang University1 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2021年4月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- Rate of grade 3 or 4 treatment related adverse effect
研究概览
简要总结
This study evaluates the safety and efficacy of novel BCMA-targeted CAR-T cell therapy (CBG-002) for patients with relapsed or refractory multiple myeloma (r/r MM). CBG-002 is designed based on the fourth-generation of CAR-T techonology.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with relapsed/refractory multiple myeloma aged 18-75 years;
- •BCMA expression ≥50% in bone marrow samples confirmed by Flow Cytometry or IHC is positive for BCMA expression;
- •Relapsed/refractory patients who meet the following conditions:
- •Ineffective or disease progression after receiving bortezomib (proteasome inhibitor) and lenalidomide for 3 courses;
- •Ineffective or disease progression after receiving the original treatment plan for 3 courses;
- •The interval between the last treatment and disease progression is more than 30 days;
- •There is currently no indication for hematopoietic stem cell transplantation, or the patient refuses to do hematopoietic stem cell transplantation;
- •The definition of disease progression refers to the "2014 IMWG Standards", and at least meets the following 1 items:
- •e.1 Serum M protein ≥ 0.5 g/dL;
- •e.2 Urine M protein ≥ 200 mg/24 h;
- •e.3 If the serum FLC ratio is abnormal, the patient's FLC level ≥ 10 mg/dL (100 mg/L);
- •e.4 Evaluable plasmacytoma confirmed by biopsy;
- •e.5 Increase in the proportion of bone marrow plasma cells ≥25% (absolute increase ≥10%);
- •e.6 Bone marrow plasma cells account for 30% of the total bone marrow cells;
- •Estimated survival time> 12 weeks;
- •The disease status can be assessed and meet at least one of the following:
- •Serum M-protein ≥10 g/L;
- •24h urine M-protein ≥200mg;
- •Serum FLC≥5mg/dL;
- •Plasma cell tumors that can be assessed by testing or images;
- •The proportion of bone marrow plasma cells ≥ 30%;
- •ECOG physical status score 0-1;
- •Have enough venous access for apheresis or venous blood collection, and there are no other contraindications for blood cell separation;
- •WBC ≥ 1.5×109/L; PLT ≥ 45×109/L;
- •Serum creatinine ≤ 1.5 upper limit of normal (ULN) ;
- •ALT ≤ 2.5 ULN, AST ≤ 2.5 ULN.
- •All laboratory test results within the above range should have no ongoing continuous supportive treatment.
排除标准
- •Subjects who meet any of the following criteria cannot be selected for this study:
- •Systemic treatment such as lymphatic depletion with cyclophosphamide and fludarabine within 2 weeks before enrollment or single cell collection, or cell therapy within 8 weeks before treatment;
- •HCV or HIV positive; any uncontrollable active infection, including active tuberculosis, HBV DNA level ≥1×103 copies/mL;
- •Active infections occurred within 72 hours before cleansing; as long as there is no evidence of active infection and antibiotics are not in the list of prohibited drugs, subjects who continue to use preventive antibiotics, antifungal drugs or antiviral drugs are not excluded;
- •The current systemic use of cyclosporine or steroid drugs such as dexamethasone, recent or current use of inhaled steroids is not excluded;
- •Renal insufficiency, serum creatinine>1.5 upper limit of normal (ULN);
- •Liver insufficiency, aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT)>2.5 times ULN and direct bilirubin>1.5 times ULN;
- •Hyponatremia, blood sodium <125 mmol/L;
- •Baseline serum potassium <3.5 mmol/L (potassium supplementation can be given before participating in the study, and serum potassium recovery above this standard is not excluded);
- •Pregnant or lactating women;
- •Other serious diseases that may restrict subjects from participating in this trial (such as central nervous system disease, severe heart insufficiency, myocardial obstruction or unstable arrhythmia or unstable angina, gastric ulcer in the past 6 months , Active autoimmune diseases, etc.).
研究组 & 干预措施
Anti-BCMA CAR-T (CBG-002)
Experimental
All subjects were intravenous administrated with CBG-002.
干预措施: anti-BCMA CAR-T (Biological)
Anti-BCMA CAR-T (CBG-002)
Experimental
All subjects were intravenous administrated with CBG-002.
干预措施: Cyclophosphamid (Drug)
Anti-BCMA CAR-T (CBG-002)
Experimental
All subjects were intravenous administrated with CBG-002.
干预措施: Fludarabine (Drug)
结局指标
主要结局
Rate of grade 3 or 4 treatment related adverse effect
时间窗: 24 weeks after last dose of CAR-T treatment
All the CAR-T treatment related adverse events，including Dose limiting toxicity (DLT), cytokine release syndrome (CRS), CAR-T associated encephalopathy syndrome, will be assessed and graded by NCI CTCAE v 5.0.
Overall response rate (ORR) after treated by CAR-T treatment
时间窗: up to 2 years after CAR-T treatment
ORR will be assessed and graded by the international Myeloma Working Group (IMWG) Unified response criteria for multiple myeloma
次要结局
- Overall survival(up to 2 years after CAR-T treatment)
- Progression free survival(up to 2 years after CAR-T treatment)
- Pharmacokinetics of CAR-T cells (implantation endpoint)(up to 2 years after CAR-T treatment)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple MyelomaNew Diagnosis TumorMultiple MyelomaNCT05712083Zhejiang University40
Unknown
1 期
Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple MyelomaMultiple Myeloma in RelapseNeoplasm, Plasma CellMultiple MyelomaNCT04272151Chongqing Precision Biotech Co., Ltd40
招募中
2 期
BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCTMultiple MyelomaNCT05846737Institute of Hematology & Blood Diseases Hospital, China20
招募中
早期 1 期
A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple MyelomaRelapse Multiple MyelomaRefractory Multiple MyelomaNCT05430945Zhejiang University100
招募中
1 期
BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell DiseaseNeoplasm, Plasma CellMultiple Myeloma in RelapseMultiple MyelomaNCT04271644Chongqing Precision Biotech Co., Ltd80